What is the significance of a 3 mm solid nodule anterior to the psoas muscle in a patient with a history of partial nephrectomy for chromophobe renal cell carcinoma (RCC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The presence of a 3 mm solid nodule anterior to the psoas muscle in a patient with a history of partial nephrectomy for chromophobe renal cell carcinoma (RCC) warrants close monitoring, and I recommend a follow-up CT or MRI in 3-6 months to reassess the nodule's characteristics and growth pattern. Given the patient's history of chromophobe RCC, which is generally associated with a good prognosis and low metastatic potential, especially at the T1A stage 1, this nodule requires monitoring but is not necessarily cause for immediate concern. The location anterior to the psoas muscle and below the kidney suggests it could be a lymph node or soft tissue change related to the surgery.

Some key points to consider in the management of this patient include:

  • The importance of continued surveillance after partial nephrectomy for RCC, as most recurrences occur within 3 years after treatment 1
  • The use of imaging modalities such as CT and MRI for follow-up, with the frequency and duration of follow-up depending on the patient's risk factors and tumor characteristics 1
  • The consideration of biopsy if the follow-up imaging shows growth or concerning features, to determine the nature of the nodule 1
  • The prognostic factors that are validated by the International Society of Urological Pathology (ISUP) consensus and the WHO 2016 classification of RCC, including the tumor histological subtype, ISUP nucleolar grade, and the presence of sarcomatoid and/or rhabdoid differentiation 1

Overall, the management of this patient should be individualized based on their specific clinical and pathological characteristics, and should involve close monitoring and follow-up to detect any potential recurrence or progression of disease. A follow-up CT or MRI in 3-6 months is recommended to reassess the nodule's characteristics and growth pattern, and to guide further management.

From the Research

Clinical Significance of a 3 mm Solid Nodule

The presence of a 3 mm solid nodule anterior to the psoas muscle in a patient with a history of partial nephrectomy for chromophobe renal cell carcinoma (RCC) may indicate a potential recurrence or metastasis of the disease.

  • The study 2 highlights the importance of considering the variable features of renal cell carcinoma subtypes in narrowing down the differential diagnosis.
  • Another study 3 discusses the challenges of managing local recurrence after partial nephrectomy, including the options of ablative therapy or surgical salvage therapy.
  • A clinicopathological study 4 of 16 cases of chromophobe RCC found that patients with pure chromophobe RCC had a favorable prognosis, while those with mixed types including aggressive elements had a poor clinical course.

Recurrence and Metastasis

The possibility of recurrence or metastasis in a patient with a history of chromophobe RCC cannot be ruled out, even with a small nodule size.

  • A case report 5 describes a unique instance of chromophobe RCC seeding after biopsy, resulting in tumor recurrence on the posterior abdominal wall.
  • An analysis of 53 cases of chromophobe RCC 6 found that tumor metastasis was discovered in 2 patients, highlighting the need for ongoing surveillance and monitoring.

Diagnostic Considerations

The diagnosis and management of a 3 mm solid nodule in this context would require careful consideration of the patient's history, imaging findings, and potential biopsy results.

  • The study 2 emphasizes the importance of knowledge of the variable common features of renal cell carcinoma subtypes in guiding appropriate surgical management.
  • The case report 3 highlights the challenges of managing local recurrence after partial nephrectomy and the need for individualized treatment approaches.

Related Questions

What is the significance of a 3 mm nodule in the fat anterior to the psoas muscle, present one month post-partial nephrectomy for chromophobe Renal Cell Carcinoma (RCC) and persisting over three years?
What is the significance of a persistent 3 mm nodule anterior to the psoas muscle, adjacent to the left kidney, after partial nephrectomy for Chromophobe renal cell carcinoma (RCC)?
What is the significance of a 3 mm nodule near the left kidney in a patient with a history of partial nephrectomy for Chromophobe renal cell carcinoma (RCC)?
Is a 3mm nodule, visible on CT imaging 3 years after partial nephrectomy for stage 1 Chromophobe Renal Cell Carcinoma (RCC), located in the fat anterior to the psoas muscle below the lower pole of the left kidney, likely benign?
Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC), represent a malignant or benign process?
What research exists on heart rate variability (HRV)?
What is the significance of a 3 mm solid nodule anterior to the psoas muscle in a patient with a history of partial nephrectomy for chromophobe renal cell carcinoma (RCC)?
What is the significance of a 3 mm solid nodule anterior to the psoas muscle in a patient with a history of partial nephrectomy for chromophobe renal cell carcinoma (RCC)?
What is the recommended dose of Vancomycin (Vancomycin) for treating meningitis?
What is the specific treatment for a 30-year-old male patient with Plasmodium vivax (P. vivax) malaria?
What is the significance of a newly defined 3mm nodule adjacent to the left kidney three years after partial nephrectomy for T1A chromophobe Renal Cell Carcinoma (RCC)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.